Topics

WuXi Biologics acquires first EU drug product facility through Bayer deal

09:21 EST 16 Jan 2020 | BioPharma-Reporter

WuXi Biologics will add Bayerâs Leverkusen drug product facility, as part of its continued expansion into the European market.

Original Article: WuXi Biologics acquires first EU drug product facility through Bayer deal

NEXT ARTICLE

More From BioPortfolio on "WuXi Biologics acquires first EU drug product facility through Bayer deal"

Quick Search

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...